InMode Ltd. (INMD) fair value analysis

Nasdaq · Updated 2026-09-07

InMode Ltd. is a medical device company that develops and markets minimally invasive aesthetic and surgical treatment systems. The company operates globally with a presence in multiple markets across North America, Europe, and other regions.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, INMD is trading at a 10–25% premium to estimated fair value.

INMD currently ranks #93 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $15.35
Sector: Healthcare
12-month range: $13.59–$16.62

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Low
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The upper-middle quarter of its range

What our data shows for INMD

Our model validated 17 trailing price-to-earnings windows for INMD, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $13.59–$16.62.
The 14-day relative strength index sits at a neutral 43.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for INMD
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent INMD news

TickrTrends' derived news-sentiment signal for INMD is currently mixed, computed from recent coverage.

InMode Ltd. (INMD) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:INMD) 2026-06-04 (seekingalpha.com, 2026-06-04)
TickrTrends take: InMode's presentation at the Jefferies Global Healthcare Conference provides an opportunity for investors to assess whether the company's growth narrative justifies its current valuation, which TickrTrends rates as overvalued. Given that the Healthcare sector contains many companies competing for investor capital, the slideshow content will be relevant for determining if INMD can demonstrate competitive advantages or margin expansion sufficient to support a premium valuation. Valuation-focused investors should pay particular attention to any updates on revenue growth rates, market expansion, and profitability trends that might either validate or challenge the overvalued assessment.
InMode: My Pick For A Major Turnaround In 2026 And 2027 (NASDAQ:INMD) (seekingalpha.com, 2026-05-28)
TickrTrends take: InMode operates in the Healthcare sector and is currently assessed as overvalued according to TickrTrends valuation metrics. An investor focused on valuation should monitor whether the company's operational performance in 2026 and 2027 materializes sufficiently to justify its current pricing, or whether the overvalued status persists. The gap between current valuation and underlying business fundamentals will be a key factor in determining whether any projected turnaround translates into value creation for shareholders at present price levels.
InMode Ltd. (INMD) Q1 2026 Earnings Call Transcript (seekingalpha.com, 2026-05-06)
TickrTrends take: InMode Ltd. operates in the Healthcare sector where investors typically scrutinize the relationship between revenue growth, profitability, and valuation multiples. TickrTrends currently marks INMD as overvalued, which suggests that at present market pricing, the company's financial metrics may not justify its stock price relative to peers or historical norms. A valuation-focused reader should examine the Q1 2026 earnings results to determine whether management's guidance and operational performance support a re-rating or reinforce concerns about stretched valuations in the medical aesthetics and surgical device space.

What people are saying

Follow the INMD conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is INMD stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), INMD is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is INMD's TickrTrends verdict?

INMD's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does INMD compare to other Healthcare stocks?

INMD ranks #93 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is INMD overbought or oversold?

INMD's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

INMD vs BIO · INMD vs CAH · INMD vs CNC · INMD vs CVS · INMD vs ILMN